Inactive Instrument

Medisun Precision Medicine Ltd.

MPME

MHY595141026

Advanced Medical Equipment & Technology

Cyto Wave Technologies Inc. will Change its Ticker to ACXA from CWAV

August 21, 2014 at 09:30 am IST

Effective August 21, 2014, Cyto Wave Technologies Inc. will change its OTC Bulletin Board stock ticker symbol to ACXA from CWAV.

Latest news about Medisun Precision Medicine Ltd.

Medisun Precision Medicine Ltd. acquired New Sonic Global Limited from Sun Medical Operation Company Limited for $3.8 million.	25/17/25	CI
Accurexa, Inc. Enters into a License Agreement with Medisun Holdings Limited to Use Medisun's NK Cell Technology	09/17/09	CI
Accurexa, Inc. Announces Management Changes	20/17/20	CI
Accurexa, Inc. Appoints Stefan Moll as Chief Financial Officer	02/17/02	CI
Accurexa Inc. Enters into Sublicense Agreement with CNMRGS Inc	07/17/07	CI
Accurexa, Inc. Announces Management Changes	19/17/19	CI
Accurexa Partners with Stemimmune to Develop Stem Cell-Mediated Immunotherapy for Cancer Patients	18/16/18	CI
DelMar Pharmaceuticals and Accurexa to Collaborate in the Development of a Novel Combination Chemotherapy for the Local Treatment of Brain Cancer	07/16/07	CI
Medisun Precision Medicine Ltd. Auditor Raises 'Going Concern' Doubt	06/15/06	CI
Accurexa Inc. Announces Directorate Changes	02/15/02	CI
Medisun Precision Medicine Ltd. announced that it has received $2.25 million in funding	22/15/22	CI
Accurexa Inc. announced that it expects to receive $2.25 million in funding.	16/15/16	CI
Accurexa Seeks Financing	25/15/25	CI
Accurexa, Inc. Enters into an Exclusive License Agreement with the Regents of the University of California	18/14/18	CI
Cyto Wave Technologies Inc. will Change its Name to Accurexa Inc	21/14/21	CI
Cyto Wave Technologies Inc. will Change its Ticker to ACXA from CWAV	21/14/21	CI
Cyto Wave Technologies Inc. Appoints Luc H. Meyer as Director	11/13/11	CI
Cyto Wave Technologies Inc. announced that it has received $0.97 million in funding	29/12/29	CI
Cyto Wave Technologies Inc. announced that it expects to receive $1 million in funding.	14/12/14	CI

Chart Medisun Precision Medicine Ltd.

Duration

Period

More charts

Medisun Precision Medicine Ltd. is a development-stage company. The Company is focused on developing neurological therapies to be directly delivered into specific regions of the brain. The Company is developing its ACX-31 program to deliver approximately two chemotherapy drugs, temozolomide in combination with biodegradable 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) locally to brain tumor sites. Through its second development program, it is developing BranchPoint device that can deliver therapeutics through the radial deployment of a delivery catheter to large and anatomically complex brain targets through a single initial brain penetration. It is based on a neurosurgical delivery platform, which can enable approaches to neurological therapy and be modified for the delivery of a range of therapeutics, such as stem cells to treat neurodegenerative diseases, chemotherapeutics to brain tumors and gene therapy vectors.

Sector

Advanced Medical Equipment & Technology

More about the company

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
THERMO FISHER SCIENTIFIC	+10.03%	22TCr
DANAHER CORPORATION	+13.59%	19TCr
INTUITIVE SURGICAL, INC.	+20.01%	14TCr
BOSTON SCIENTIFIC CORPORATION	+30.83%	11TCr
SIEMENS HEALTHINEERS AG	+2.28%	6.5TCr
EDWARDS LIFESCIENCES CORPORATION	+15.38%	5.3TCr
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+3.64%	5.04TCr
AGILENT TECHNOLOGIES, INC.	+8.37%	4.42TCr
GE HEALTHCARE TECHNOLOGIES INC.	+3.27%	3.64TCr

Other Advanced Medical Equipment & Technology

Medisun Precision Medicine Ltd.

Equities

MPME

MHY595141026

Advanced Medical Equipment & Technology

Cyto Wave Technologies Inc. will Change its Ticker to ACXA from CWAV

Latest news about Medisun Precision Medicine Ltd.

Chart Medisun Precision Medicine Ltd.

Company Profile

Sector Other Advanced Medical Equipment & Technology